Divergent Effects of α-Tocopherol and Vitamin C on the Generation of Dysfunctional HDL Associated with Diabetes and the Hp 2-2 Genotype

被引:27
作者
Asleh, Rabea [1 ]
Levy, Andrew P. [1 ]
机构
[1] Technion Israel Inst Technol, Technion Fac Med, IL-31096 Haifa, Israel
基金
以色列科学基金会;
关键词
HAPTOGLOBIN GENOTYPE; CARDIOVASCULAR-DISEASE; IN-VITRO; E SUPPLEMENTATION; INDIVIDUALS; ANTIOXIDANT; IRON; ATHEROSCLEROSIS; HEMOGLOBIN; RISK;
D O I
10.1089/ars.2009.2829
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
The haptoglobin (Hp) 2-2 genotype is associated with increased risk of cardiovascular disease (CVD) in diabetes (DM). We recently proposed this increased risk arises from the tethering of redox active hemoglobin (Hb) to high density lipoprotein (HDL), thereby resulting in oxidative modification of HDL. Clinical trials have demonstrated that vitamin E (alpha-tocopherol) decreases while vitamin C increases CVD in Hp 2-2 DM individuals. We sought to test the hypothesis that the interaction of alpha-tocopherol or vitamin C on CVD in Hp 2-2 DM was due to their divergent effects on HDL oxidation and function. Vitamin C significantly increased while alpha-tocopherol completely blocked oxidation mediated by glycosylated Hb-Hp 2-2. Vitamin C had no benefit while alpha-tocopherol completely restored HDL function in Hp 2-2 DM mice. Co-administration of vitamin C mitigated the protective effects of alpha-tocopherol on HDL. There exists a pharmacogenomic interaction between vitamin C and alpha-tocopherol and the Hp 2-2 genotype on HDL function and structure. Choosing the correct antioxidant in the correct subset of patients may be critical in order to demonstrate benefit from antioxidant therapy. Antioxid. Redox Signal. 12, 209-218.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 39 条
[1]
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo [J].
Asleh, R ;
Guetta, J ;
Kalet-Litman, S ;
Miller-Lotan, R ;
Levy, AP .
CIRCULATION RESEARCH, 2005, 96 (04) :435-441
[2]
Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype [J].
Asleh, Rabea ;
Blum, Shany ;
Kalet-Litman, Shiri ;
Alshiek, Jonia ;
Miller-Lotan, Rachel ;
Asaf, Roy ;
Rock, Wasseem ;
Aviram, Michael ;
Milman, Uzi ;
Shapira, Chen ;
Abassi, Zaid ;
Levy, Andrew P. .
DIABETES, 2008, 57 (10) :2794-2800
[3]
Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo [J].
Asleh, Rabea ;
Miller-Lotan, Rachael ;
Aviram, Michael ;
Hayek, Tony ;
Yulish, Michael ;
Levy, Joanne E. ;
Miller, Benjamin ;
Blum, Shany ;
Milman, Uzi ;
Shapira, Chen ;
Levy, Andrew P. .
CIRCULATION RESEARCH, 2006, 99 (12) :1419-1425
[4]
PLASMA-LIPOPROTEIN SEPARATION BY DISCONTINUOUS DENSITY GRADIENT ULTRA-CENTRIFUGATION IN HYPERLIPOPROTEINEMIC PATIENTS [J].
AVIRAM, M .
BIOCHEMICAL MEDICINE, 1983, 30 (01) :111-118
[5]
Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL [J].
Bamm, VV ;
Tsemakhovich, VA ;
Shaklai, M ;
Shaklai, N .
BIOCHEMISTRY, 2004, 43 (13) :3899-3906
[6]
Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease [J].
Blum, Shany ;
Milman, Uzi ;
Shapira, Clien ;
Levy, Andrew P. .
PHARMACOGENOMICS, 2008, 9 (08) :989-991
[7]
BOWMAN BH, 1982, ADV HUM GENET, V12, P189
[8]
Is there any hope for vitamin E? [J].
Brown, BG ;
Crowley, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (11) :1387-1390
[9]
Ceriello Antonio, 2006, Endocr Pract, V12 Suppl 1, P60
[10]
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3